Quantcast
Last updated on April 23, 2014 at 12:16 EDT

Latest autoimmune diseases Stories

2014-01-16 16:24:09

AUSTIN, Texas, Jan. 16, 2014 /PRNewswire/ -- XBiotech announced today that it has launched a Phase II study to treat a rare but debilitating disorder, Pyoderma Gangrenosum (PG). This study is based on efficacy seen with anti-IL-1 therapeutic antibody in previous dermatological clinical studies such as psoriasis and acne. PG is expected to be considered an "orphan indication" by the FDA, facilitating expedited clinical development to market. Dr. Armand Cognetta, lead clinical...

2014-01-15 08:29:25

Collaboration Brings Unique Expertise Together THOUSAND OAKS, Calif., Jan. 15, 2014 /PRNewswire/ -- Massachusetts General Hospital (MGH), the Broad Institute, and Amgen (NASDAQ:AMGN) announced today that they have launched a strategic collaboration to jointly discover and validate new therapeutic targets and develop novel therapies for inflammatory bowel disease (IBD), a chronic disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration brings together...

2014-01-14 16:25:08

Brings Total to $6.6 Million to Educate Healthcare Professionals on Front-Lines of Care NEW YORK, Jan. 14, 2014 /PRNewswire/ -- The 2014 Omnibus Appropriations Bill released by the U.S. Congress last night provides $2 million to further the Lupus Initiative, the lupus provider education program conceived by the Lupus Research Institute (LRI) in collaboration with the federal government. Expected to pass this week, the appropriation will bring total support to $6.6 million for the...

2014-01-13 08:26:42

PETACH TIKVA, Israel, Jan. 13, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it will present new data based on a further analysis of results from its Phase IIb study of CF101 for the treatment of Rheumatoid Arthritis and interim data from its Phase II/III study of CF101 for the treatment of Psoriasis at the...

FDA Approves Novel AstraZeneca, Bristol-Meyers Squibb Diabetes Drug
2014-01-10 11:37:58

Ranjini Raghunath for redOrbit.com - Your Universe Online The FDA has approved the use of a new Type 2 diabetes drug called Farxiga, developed by pharmaceutical companies Bristol-Meyers Squibb and AstraZeneca. Type 2 diabetes affects 24 million people in the US and nearly 350 million people worldwide. Conventional diabetes drugs work by reducing the amount of sugar the body absorbs from food or by boosting the production of insulin which disposes of excess sugar. Farxiga, however,...

2014-01-09 23:26:38

Dr. James Wells, of South Charlotte Dentistry, is excited about sharing information about Rheumatoid Arthritis as it relates to dental health with his patients and the community. (PRWEB) January 09, 2014 In recent years, we’ve learned more and more about the link between a healthy mouth and a healthy body. But now research is pointing to specific connections of certain types of bacteria and diseases, in particular Rheumatoid Arthritis (RA). Dr. James Wells, of South Charlotte...

2014-01-09 08:28:46

Renewed commitment over two years helps support education for students with type 1 diabetes INDIANAPOLIS and ROLLING MEADOWS, Ill., Jan. 9, 2014 /PRNewswire/ -- Today Lilly Diabetes announced it will renew its commitment to the Diabetes Scholars Foundation (Foundation) scholarship fund for another two years. The commitment includes a $200,000 donation ($100,000 for each calendar year) that will support the Foundation's mission: to empower young people with type 1 diabetes to live...

2014-01-09 08:28:44

OKLAHOMA CITY, Jan. 9, 2014 /PRNewswire/ -- Altheus Therapeutics, Inc., announced that it has completed enrollment for ZA201, a 6-week, double-blind, active-controlled Phase 2 clinical trial of the efficacy and safety of Zoenasa® Rectal Gel in approximately 120 adult patients with left-sided, or distal, ulcerative colitis. Topline results are expected in to be available in March or early April. (Logo: http://photos.prnewswire.com/prnh/20140109/DA43446LOGO) "Positive ZA201...

2014-01-08 08:28:37

HERZLIYA, Israel, January 8, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced it has signed a licensing agreement with Yeda Research and Development Company Ltd. ("Yeda") to develop hCDR1, a Phase II-ready asset for the treatment of...

2014-01-07 04:21:03

LONDON, January 7, 2014 /PRNewswire/ -- ~ ST10 strongly demonstrates potential to be (1) the only effective oral treatment for ferrous intolerant IDA patients and (2) an effective alternative to intravenous iron treatment ~ Shield Therapeutics (Shield), an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces strongly positive top-line data from...